Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Show more
39 John F. Kennedy Street, Cambridge, MA, 02138, United States
Market Cap
1.143B
52 Wk Range
$16.12 - $35.29
Previous Close
$27.45
Open
$27.67
Volume
113,235
Day Range
$27.41 - $29.24
Enterprise Value
1.165B
Cash
328.9M
Avg Qtr Burn
-19.81M
Insider Ownership
37.23%
Institutional Own.
18.86%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
AD109 (proposed brand: Oxnimbi) Details Obstructive sleep apnea | PDUFA Approval decision |